Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Retained Earnings (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Retained Earnings for 16 consecutive years, with $474.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 66.29% year-over-year to $474.2 million, compared with a TTM value of $474.2 million through Dec 2025, up 66.29%, and an annual FY2025 reading of $474.2 million, up 66.29% over the prior year.
  • Retained Earnings was $474.2 million for Q4 2025 at Catalyst Pharmaceuticals, up from $446.8 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $474.2 million in Q4 2025 and bottomed at -$46.3 million in Q1 2021.
  • Average Retained Earnings over 5 years is $64.0 million, with a median of $14000.0 recorded in 2023.
  • The sharpest move saw Retained Earnings crashed 3175466.75% in 2021, then soared 2036764.29% in 2024.
  • Year by year, Retained Earnings stood at -$148000.0 in 2021, then soared by 116.22% to $24000.0 in 2022, then tumbled by 41.67% to $14000.0 in 2023, then skyrocketed by 2036764.29% to $285.2 million in 2024, then skyrocketed by 66.29% to $474.2 million in 2025.
  • Business Quant data shows Retained Earnings for CPRX at $474.2 million in Q4 2025, $446.8 million in Q3 2025, and $31000.0 in Q2 2025.